Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients with type 2 diabetes and insufficient glycaemic control.~* Age 18 or over and not older than 80 years~Exclusion criteria:~* Use of more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP-1 analogues within 3 months.~* Myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin 5 mg (Type: EXPERIMENTAL): linagliptin 5 mg once daily
- placebo (Type: PLACEBO_COMPARATOR): placebo matching linagliptin 5 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).